Jan 28, 2025 · It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

6 days ago · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD).. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial ...

Jan 30, 2025 · The double-blind, placebo-controlled trial compared injectable semaglutide (1.0 mg) with a placebo as an adjunct treatment to standard of care for chronic kidney disease.

Feb 3, 2025 · FDA approves Ozempic ® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. News ...

5 days ago · Ozempic (semaglutide) is a once-weekly injection that’s approved to treat Type 2 diabetes, lower the risk of serious cardiovascular problems, and protect from chronic kidney disease in certain groups.

Find out how Ozempic® (semaglutide) helped reduce the risk of chronic kidney disease progression in patients with T2D. Read Important Safety and Prescribing Information, including Boxed Warning on this page.

May 24, 2024 · Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic...

Jan 30, 2025 · The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease. This approval makes Ozempic the first GLP-1 treatment for patients with both conditions.

Jan 28, 2025 · Ozempic reduced the risk of severe kidney outcomes — including kidney failure, reduction in kidney function, or death from kidney or heart causes — by 24% in diabetic patients with...